Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling

Current Heart Failure Reports

Volumn 3, Issue 4, 2006, Pages 157-163

  Latini, Roberto ^a   Masson, Serge ^a   Staszewsky, Lidia ^a   Barlera, Simona ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOLOGICAL MARKER; HORMONE;

BLOOD; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HORMONES; HUMANS; MYOCARDIAL ISCHEMIA; NEUROTRANSMITTER AGENTS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 39049191353     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-006-0016-8     Document Type: Review

References (56)

1. Cohn JN, Levine TB, Francis GS, Goldsmith S: Neurohumoral control mechanisms in congestive heart failure. Am Heart J 1981, 102:509-514.
2. Packer M: The neurohormoAal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
3. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
4. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
5. Waagstein F, Bristow MR, Swedberg K, et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993, 342:1441-1446.
6. Australia/New Zealand Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997, 349:375-380.
7. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet 1999, 353:2001-2007.
8. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
9. Pfeffer MA, Swedberg K, Granger CB, et al.: CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003, 362:759-766.
10. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
11. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
12. Vasan RS: Biomarkers of cardiovaMcular disease: molecular basis and practical considerations. Circulation 2006, 113: 2335-2362. A comprehensive review of the definition, characteristics, and evaluation of currently available and future biomarkers in cardiovascular diseases.
13. Anand IS, Florea VG, Fisher L: Surrogate end points in heart failure. J Am Coll Cardiol 2002, 39:1414-1421.
14. Konstam MA: Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 2005, 96:867-871.
15. Follath F, Cleland JG, Klein W, Murphy R: Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 1998, 32:1167-1172.
16. Levine TB, Francis GS, Goldsmith SR, et al.: Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982, 49:1659-1666.
17. Swedberg K, Viquerat C, Rouleau JL, et al.: Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984, 54:783-786.
18. Goldsmith SR, Francis GS, Cowley AW Jr, et al.: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983, 1:1385-1390.
19. McMurray JJ, Ray SG, Abdullah I, et al.: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374-1379.
20. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr: Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995, 92:286-289.
21. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981, 28:89-94.
22. Sudoh T, Kangawa K, Minamino N, Matsuo H: A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
23. Shenker Y, Sider RS, Ostafin EA, Grekin RJ: Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest 1985, 76:1684-1687.
24. Mukoyama M, Nakao K, Hosoda K, et al.: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87:1402-1412.
25. Swedberg K, Cleland J, Dargie H, et al.: Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:1115-1140.
26. Munger MA, Johnson B, Amber IJ, et al.: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723-727.
27. De Feo S, Franceschini L, Brighetti G, et al.: Ischemic etiology of heart failure identifies patients with more severely impaired exercise capacity. Int J Cardiol 2005, 104:292-297.
28. Namiki A, Kubota T, Fukazawa M, et al.: Endothelin-1 concentrations in pericardial fluid are more elevated in patients with ischemic heart disease than in patients with nonischemic heart disease. Jpn Heart J 2003, 44:633-644.
29. Latini R, Masson S, Anand I, et al.: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292-299.
30. Hartmann F, Packer M, Coats AJ, et al.: Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004, 110:1780-1786.
31. Richards AM, Doughty R, Nicholls MG, et al.: Plasma Nterminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001, 37:1781-1787.
32. Mantymaa P, Vuolteenaho O, Marttila M, Ruskoaho H: Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 1993, 133:1470-1473.
33. Kjaer A, Hildebrandt P, Appel J, Petersen CL: Neurohormones as markers of right- and left-sided cardiac dimensions and function in patients with untreated chronic heart failure. Int J Cardiol 2005, 99:301-306.
34. Talens-Visconti R, Rivera Otero M, Sancho-Tello MJ, et al.: Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure. Eur J Echocardiogr 2006, 7:45-52.
35. Groenning BA, Nilsson JC, Sondergaard L, et al.: Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001, 3:699-708.
36. Nelson CA, Case C, McCrohon J, Marwick TH: Relationship of extent and nature of dysfunctional myocardium to brain natriuretic peptide in patients with ischemic left ventricular dysfunction. Int J Cardiovasc Imaging 2005, 21:295-300.
37. Lowbeer C, Gustafsson SA, Seeberger A, et al.: Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest 2004, 64:667-676.
38. Iwanaga Y, Nishi I, Furuichi S, et al.: B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: Comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006, 47:742-748. LV end-diastolic wall stress is a remarkably robust determinant of cardiac secretion of BNP in patients with diastolic and systolic chronic HF.
39. Troughton RW, Prior DL, Pereira JJ, et al.: Plasma B-type natriuretic peptide levels in systolic heart failure: Importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004, 43: 416-422. BNP levels are related to LV diastolic function and to the severity of right ventricular dysfunction and mitral regurgitation in patients with systolic HF.
40. Yu CM, Sanderson JE, Shum IO, et al.: Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996, 17:1694-1702.
41. Richards M, Nicholls MG, Espiner EA, et al.: Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006, 47:52-60.
42. Masson S, Latini R, Anand IS, et al.: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) Data. Clin Chem 2006, 52:1528-1538.
43. Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970-975.
44. Goetze JP, Christoffersen C, Perko M, et al.: Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003, 17:1105-1107.
45. De Lemos JA, Morrow DA, Bentley JH, et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New Engl J Med 2001, 345:1014-1021.
46. Galvani M, Ottani F, Oltrona L, et al.: N-terminal probrain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004, 110:128-134.
47. Kragelund C, Grønning B, Køber L, et al.: N-terminal probrain natriuretic peptide and long-term mortality in stable coronary heart disease. New Engl J Med 2005, 352:666-675.
48. Yan RT, White M, Yan AT, et al.: Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005, 96:698-704.
49. Latini R, Masson S, Wong M, et al.: Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006, 119:7023-30.
50. Groenning BA, Nilsson JC, Hildebrandt PR, et al.: Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. Eur J Heart Fail 2002, 4:635-646.
51. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000, 101:378-384.
52. Gackowski A, Isnard R, Golmard JL, et al.: Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004, 25:1788-1796.
53. Battaglia M, Pewsner D, Juni P, et al.: Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: Systematic review of test accuracy studies. Arch Intern Med 2006, 166:1073-1080.
54. Freitag MH, Vasan RS: Screening for left ventricular systolic dysfunction: The use of B-type natriuretic peptide. Heart Fail Monit 2003, 4:38-44.
55. Richards AM, Troughton R, Lainchbury J, et al.: Guiding and monitoring of heart failure therapy with NT-ProBNP: Concepts and clinical studies. J Card Fail 2005, 11: S34-37.
56. Jourdain P, Funck F, Gueffet P, et al.: Benefit of BNP plasma levels for optimising therapy: The systolic heart failure treatment supported by BNP multicenter randomised trial (STARS-BNP) [abstract]. J Am Coll Cardiol 2005, 45(Suppl1):3A.